Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome
Open accessAbstract
Background Treatments for Churg-Strauss syndrome (CSS), a rare eosinophilic vasculitis characterized by asthma, sinusitis, peripheral eosinophilia, pulmonary infiltrates, and tissue infiltration, are limited by toxicity or poor efficacy. Levels of IL-5, a cytokine regulating eosinophils, can be increased in patients with CSS. Mepolizumab, a humanized monoclonal anti-IL-5 antibody, decreases steroid requirements in patients with non-CSS hypereosinophilic syndromes.Objective The purpose of this study was to assess whether mepolizumab would safely allow corticosteroid tapering in patients with steroid-dependent CSS while decreasing serum markers of disease activity.Methods This open-label pilot study treated 7 patients with 4 monthly doses of mepolizumab to assess whether it safely decreased CSS disease activity and permitted tapering of systemic corticosteroids.Results Mepolizumab was safe and well tolerated in patients with CSS. Mepolizumab reduced eosinophil counts and allowed for safe corticosteroid reduction in all 7 subjects. On cessation of mepolizumab, CSS manifestations recurred, necessitating corticosteroid bursts.Conclusion Mepolizumab is a safe and well-tolerated therapy in patients with CSS, offering clinical benefit by enabling corticosteroid tapering while maintaining clinical stability.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Anti-IL-5 therapy (mepolizumab) is a potential biological treatment for EGPA offering clinical benefit and stability and reducing corticosteroid needs.
“Anti-IL-5 therapy (mepolizumab) is a potential biological treatment offering clinical benefit and stability and reducing corticosteroid needs.252”
From International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (2018) · cites this paper as [252]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Development and validation of a questionnaire to measure asthma control
Juniper, E. F., O′byrne, P. M., Guyatt, G. H., Ferrie, P. J., & King, D. R. (1999) · European Respiratory Journal · doi:10.1034/j.1399-3003.1999.14d29.x · Cited by 2,473 · see citing works
Masi, A. T., Hunder, G. G., Lie, J. T., Michel, B. A., Bloch, D. A., Arend, W. P., Calabrese, L. H., Edworthy, S. M., Fauci, A. S., Leavitt, R. Y., et al. (1990) · Arthritis & Rheumatism · doi:10.1002/art.1780330806 · Cited by 2,212 · see citing works
Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma
Haldar, P., Brightling, C. E., Hargadon, B., Gupta, S., Monteiro, W. R., Sousa, A. R., Marshall, R. P., Bradding, P. H., Green, R. H., Wardlaw, A. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808991 · Cited by 1,862 · see citing works
Leckie, M. J., Brinke, A. T., Khan, J., Diamant, Z., O'Connor, B. J., Walls, C. M., Mathur, A., Cowley, H., Chung, K. F., Djukanović, R., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03496-6 · Cited by 1,810 · see citing works
Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia
Nair, P. K., Pizzichini, M. M. M., Kjarsgaard, M., Inman, M. D., Efthimiadis, A., Pizzichini, E., Hargreave, F. E., & O’Byrne, P. M. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805435 · Cited by 1,346 · see citing works
Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis.
Luqmani, R. A., BACON, P. A., Moots, R. J., Janssen, B. A., Pall, A. A., Emery, P., Savage, C. O. S., & Adu, D. (1994) · PubMed · Cited by 1,056 · see citing works
Interleukin-5, eosinophils, and disease
Sanderson, C. (1992) · Blood · doi:10.1182/blood.v79.12.3101.bloodjournal79123101 · Cited by 972 · see citing works
Interleukin-5, eosinophils, and disease
Sanderson, C. (1992) · Blood · doi:10.1182/blood.v79.12.3101.3101 · Cited by 860 · see citing works
Flood-Page, P. T., Menzies-Gow, A. N., Kay, A. B., & Robinson, D. S. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200208-789oc · Cited by 808 · see citing works
A Study to Evaluate Safety and Efficacy of Mepolizumab in Patients with Moderate Persistent Asthma
Flood-Page, P. T., Swenson, C. A., Faiferman, I., Matthews, J. G., Williams, M. J. A., Brannick, L., Robinson, D. S., Wenzel, S. E., Busse, W. W., Hansel, T. T., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200701-085oc · Cited by 750 · see citing works
Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab
Rothenberg, M. E., Klion, A. D., Roufosse, F. E., Kahn, J., Weller, P. F., Simon, H., Schwartz, L. B., Rosenwasser, L. J., Ring, J., Griffin, E. F., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa070812 · Cited by 583 · see citing works
Eosinophilia in transgenic mice expressing interleukin 5.
Dent, L. A., Strath, M., Mellor, A. L., & Sanderson, C. J. (1990) · The Journal of Experimental Medicine · doi:10.1084/jem.172.5.1425 · Cited by 579 · see citing works
KIPS, J. C., O'Connor, B. J., Langley, S. J., Woodcock, A. A., Kerstjens, H. A. M., Postma, D. S., Danzig, M., Cuss, F. M., & PAUWELS, R. A. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200206-525oc · Cited by 494 · see citing works
Anti–IL-5 (mepolizumab) therapy for eosinophilic esophagitis
Stein, M., Collins, M. H., Villanueva, J. M., Kushner, J. P., Putnam, P. E., Buckmeier, B. K., Filipovich, A. H., Assa’ad, A., & Rothenberg, M. E. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.09.007 · Cited by 459 · see citing works
Menzies-Gow, A. N., Flood-Page, P. T., Sehmi, R., Burman, J. F., Hamid, Q. A., Robinson, D. S., Kay, A. B., & Denburg, J. A. (2003) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2003.1382 · Cited by 276 · see citing works
Use of an Anti–Interleukin-5 Antibody in the Hypereosinophilic Syndrome with Eosinophilic Dermatitis
Plötz, S. G., Simon, H., Darsow, U. G., Simon, D., Vassina, E. M., Yousefi, S., Hein, R., Smith, T., Behrendt, H., & Ring, J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa031261 · Cited by 257 · see citing works
Long-term outcome and prognosis in oligoarticular-onset juvenile idiopathic arthritis
Guillaume, S., Prieur, A., Coste, J., & Job-Deslandre, C. (2000) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200008)43:8 · Cited by 213 · see citing works
Stein, M., Villanueva, J. M., Buckmeier, B. K., Yamada, Y., Filipovich, A. H., Assa’ad, A., & Rothenberg, M. E. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.02.033 · Cited by 143 · see citing works
Wang, J., Palmer, K., Lötvall, J. O., Milan, S., Lei, X. F., Matthaei, K., Gauldie, J., Inman, M. D., Jordana, M., & Xing, Z. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2686 · Cited by 138 · see citing works
Proinflammatory Cytokines and Autoimmunity in Churg-Strauss Syndrome
Hellmich, B., Csernok, E., & Gross, W. L. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1361.053 · Cited by 136 · see citing works
Sustained response to mepolizumab in refractory Churg-Strauss syndrome
Kahn, J., Grandpeix‐Guyodo, C., Marroun, I., Catherinot, É., Mellot, F., Roufosse, F. E., & Blétry, O. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.10.014 · Cited by 117 · see citing works
Martin, R. M., Wilton, L., & Mann, R. D. (1999) · Pharmacoepidemiology and Drug Safety · doi:10.1002/(sici)1099-1557(199905/06)8:3 · Cited by 105 · see citing works
Zia‐Amirhosseini, P., Minthorn, E. A., Benincosa, L. J., Hart, T. K., Hottenstein, C. S., Tobia, L. A. P., & Davis, C. B. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35210-3 · Cited by 77 · see citing works
Anti-Interleukin-5 Monoclonal Antibodies
Leckie, M. J. (2003) · American Journal of Respiratory Medicine · doi:10.1007/bf03256653 · Cited by 74 · see citing works
Eosinophil Active Cytokines and Surface Analysis of Eosinophils in Churg-Strauss Syndrome
Tsukadaira, A., Okubo, Y., Kitano, K., Horie, S., Momose, T., Takashi, S., Suzuki, J.-I., Isobe, M., & Sekiguchi, M. (1999) · Allergy and Asthma Proceedings · doi:10.2500/108854199778681486 · Cited by 74 · see citing works
Involvement of Soluble CD95 in Churg-Strauss Syndrome
Müschen, M., Warskulat, U., Perniok, A., Even, J., Moers, C., Kismet, B., Temizkan, N., Simon, D., Schneider, M. B., & Häussinger, D. (1999) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65191-7 · Cited by 67 · see citing works
Asthma drug use and the development of Churg–Strauss syndrome (CSS)
Harrold, L. R., Patterson, M. K., Andrade, S. E., Dube, T., Go, A. S., Buist, A. S., Chan, K. A., Weller, P. F., Wechsler, M. E., Yood, R. A., et al. (2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1353 · Cited by 60 · see citing works
Self-citationInflammatory cells and cellular activation in the lower respiratory tract in Churg-Strauss syndrome
Schnabel, A., Csernok, E., Braun, J., & Gross, W. L. (1999) · Thorax · doi:10.1136/thx.54.9.771 · Cited by 52 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- Peen E, Hahn P, Lauwers G, Williams RC Jr, Gleich G, Kephart GM. Churg- Strauss syndrome: localization of eosinophil major basic protein in damaged tissues. Arthritis Rheum 2000;43:1897-900.
Cited by
Sorted by citations
Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis
Wechsler, M. E., Akuthota, P., Jayne, D. G., Khoury, P., Klion, A. D., Langford, C. A., Merkel, P. A., Moosig, F., Specks, U., Cid, M. C., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1702079 · Cited by 1,091 · see citing works
Self-citationInternational Consensus Statement on Allergy and Rhinology: Allergic Rhinitis
Wise, S. K., Lin, S. Y., Toskala, E., Orlandi, R. R., Akdis, C. A., Alt, J. A., Azar, A., Baroody, F. M., Bachert, C., Canonica, G. W., et al. (2018) · International Forum of Allergy & Rhinology · doi:10.1002/alr.22073 · Cited by 557 · see citing works
Groh, M., Pagnoux, C., Baldini, C., Bel, E., Bottero, P., Cottin, V., Dalhoff, K., Dunogué, B., Gross, W., Holle, J., et al. (2015) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2015.04.022 · Cited by 476 · see citing works
Self-citationAssa’ad, A., Gupta, S. K., Collins, M. H., Thomson, M. A., Heath, A. T., Smith, D. A., Perschy, T. L., Jurgensen, C. H., Ortega, H. G., & Aceves, S. S. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.07.044 · Cited by 438 · see citing works
Targeting cytokines to treat asthma and chronic obstructive pulmonary disease
Barnes, P. J. (2018) · Nature reviews. Immunology · doi:10.1038/s41577-018-0006-6 · Cited by 422 · see citing works
Emmi, G., Bettiol, A., Gelain, E., Bajema, I. M., Berti, A., Burns, S., Cid, M. C., Tervaert, J. W. C., Cottin, V., Durante, E., et al. (2023) · Nature Reviews Rheumatology · doi:10.1038/s41584-023-00958-w · Cited by 343 · see citing works
Greco, A., Rizzo, M. I., VIRGILIO, A. D., Gallo, A., Fusconi, M., Ruoppolo, G., ALTISSIMI, G., & VINCENTIIS, M. D. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.12.004 · Cited by 297 · see citing works
Eosinophilic granulomatosis with polyangiitis ( C hurg– S trauss): state of the art
Vaglio, A., Buzio, C., & Zwerina, J. (2013) · Allergy · doi:10.1111/all.12088 · Cited by 283 · see citing works
Moosig, F., Bremer, J. P., Hellmich, B., Holle, J. U., Holl-Ulrich, K., Laudien, M., Matthis, C., Metzler, C., Nölle, B., Richardt, G., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-201531 · Cited by 279 · see citing works
Biomarkers for severe eosinophilic asthma
Yancey, S. W., Keene, O. N., Albers, F. C., Ortega, H. G., Bates, S., Bleecker, E. R., & Pavord, I. D. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.10.005 · Cited by 229 · see citing works
Molecular and clinical rationale for therapeutic targeting of interleukin‐5 and its receptor
Molfino, N. A., Gossage, D. L., Kolbeck, R., Parker, J. M., & Geba, G. P. (2011) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2011.03854.x · Cited by 217 · see citing works
Eosinophilic Granulomatosis with Polyangiitis: An Overview
Gioffredi, A., Maritati, F., Oliva, E., & Buzio, C. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00549 · Cited by 217 · see citing works
Targeting Interleukin-5 in Refractory and Relapsing Churg–Strauss Syndrome
Moosig, F., Gross, W. L., Herrmann, K., Bremer, J. P., & Hellmich, B. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-5-201109060-00026 · Cited by 205 · see citing works
Eosinophilic granulomatosis with polyangiitis: understanding the disease and its management
Trivioli, G., Terrier, B., & Vaglio, A. (2019) · Lara D. Veeken · doi:10.1093/rheumatology/kez570 · Cited by 193 · see citing works
Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than Asthma
Roufosse, F. E. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00049 · Cited by 191 · see citing works
Eosinophils in vasculitis: characteristics and roles in pathogenesis
Khoury, P., Grayson, P. C., & Klion, A. D. (2014) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2014.98 · Cited by 182 · see citing works
Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders
Varricchi, G., Bagnasco, D., Borriello, F., Heffler, E. M., & Canonica, G. W. (2016) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000251 · Cited by 178 · see citing works
Eosinophilic granulomatosis with polyangiitis: A review
White, J., & Dubey, S. (2022) · Autoimmunity Reviews · doi:10.1016/j.autrev.2022.103219 · Cited by 178 · see citing works
Severe asthma: Advances in current management and future therapy
Barnes, P. J. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.11.006 · Cited by 174 · see citing works
Advances in mechanisms of asthma, allergy, and immunology in 2010
Broide, D. H., Finkelman, F. D., Bochner, B. S., & Rothenberg, M. E. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.01.027 · Cited by 172 · see citing works
Eosinophils in Autoimmune Diseases
Diny, N. L., Rose, N. R., & Čiháková, D. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00484 · Cited by 172 · see citing works
Otani, I. M., Anilkumar, A. A., Newbury, R., Bhagat, M., Beppu, L. Y., Dohil, R., Broide, D. H., & Aceves, S. S. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.02.042 · Cited by 161 · see citing works
New pathophysiological insights and treatment of ANCA-associated vasculitis
Wilde, B., van Paassen, P., Witzke, O., & Tervaert, J. W. C. (2010) · Kidney International · doi:10.1038/ki.2010.472 · Cited by 153 · see citing works
Steinfeld, J., Bradford, E., Brown, J., Mallett, S. A., Yancey, S. W., Akuthota, P., Cid, M. C., Gleich, G. J., Jayne, D. R. W., Khoury, P., et al. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.11.041 · Cited by 151 · see citing works
Self-citationCottin, V. (2016) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2016.04.015 · Cited by 146 · see citing works
Eosinophilic granulomatosis with polyangiitis (Churg–Strauss)
Mahr, A., Moosig, F., Neumann, T. E., Szczeklik, W., Taillé, C., Vaglio, A., & Zwerina, J. (2013) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000015 · Cited by 145 · see citing works
Holgate, S. T. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.06.052 · Cited by 136 · see citing works
Jacobsen, E. A., Jackson, D. J., Heffler, E. M., Mathur, S. K., Bredenoord, A. J., Pavord, I. D., Akuthota, P., Roufosse, F. E., & Rothenberg, M. E. (2021) · Annual Review of Immunology · doi:10.1146/annurev-immunol-093019-125918 · Cited by 136 · see citing works
Animal models of asthma: value, limitations and opportunities for alternative approaches
Holmes, A. M., Solari, R. C. E., & Holgate, S. T. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.05.014 · Cited by 132 · see citing works
Jakieła, B., Szczeklik, W., Plutecka, H., Sokołowska, B. M., Mastalerz, L., Sanak, M., Bazan‐Socha, S., Szczeklik, A., & Musiał, J. (2012) · Lara D. Veeken · doi:10.1093/rheumatology/kes171 · Cited by 123 · see citing works
Pharmacokinetics and Pharmacodynamics of Mepolizumab, an Anti-Interleukin-5 Monoclonal Antibody
Smith, D. A., Minthorn, E. A., & Beerahee, M. (2011) · Clinical Pharmacokinetics · doi:10.2165/11584340-000000000-00000 · Cited by 117 · see citing works
From DREAM to REALITI‐A and beyond: Mepolizumab for the treatment of eosinophil‐driven diseases
Pavord, I. D., Bel, E. H., BOURDIN, A. A., Chan, R. H., Han, J. K., Keene, O. N., Liu, M. C., Martin, N., Papi, A. A., Roufosse, F. E., et al. (2021) · Allergy · doi:10.1111/all.15056 · Cited by 116 · see citing works
Self-citationAkuthota, P., & Weller, P. F. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.00025-12 · Cited by 115 · see citing works
What targeting eosinophils has taught us about their role in diseases
Bochner, B. S., & Gleich, G. J. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.02.026 · Cited by 110 · see citing works
Eosinophils and eosinophilic immune dysfunction in health and disease
Jackson, D. J., Akuthota, P., & Roufosse, F. E. (2022) · European Respiratory Review · doi:10.1183/16000617.0150-2021 · Cited by 112 · see citing works
Jachiet, M., Samson, M., Cottin, V., Kahn, J., Guenno, G. L., Bonniaud, P., Devilliers, H., Bouillet, L., Gondouin, A., Makhlouf, F., et al. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39663 · Cited by 106 · see citing works
EAACI IG Biologicals task force paper on the use of biologic agents in allergic disorders
Boyman, O., Kaegi, C., Akdiş, M., Bavbek, S., Bossios, A., Chatzipetrou, A., Eiwegger, T., Firinu, D., Harr, T., Knol, E. F., et al. (2015) · Allergy · doi:10.1111/all.12616 · Cited by 105 · see citing works
Biologic Therapies Targeting Eosinophils: Current Status and Future Prospects
Legrand, F., & Klion, A. D. (2015) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2015.01.013 · Cited by 103 · see citing works
Allergic Comorbidity in Eosinophilic Esophagitis: Mechanistic Relevance and Clinical Implications
Capucilli, P., & Hill, D. A. (2019) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-019-08733-0 · Cited by 101 · see citing works
Novel targeted therapies for eosinophilic disorders
Wechsler, M. E., Fulkerson, P. C., Bochner, B. S., Gauvreau, G. M., Gleich, G. J., Henkel, T., Kolbeck, R., Mathur, S. K., Ortega, H. G., Patel, J., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.07.027 · Cited by 98 · see citing works
Self-citationVaglio, A., Moosig, F., & Zwerina, J. (2011) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32834d85ce · Cited by 95 · see citing works
Long-term clinical outcomes of high-dose mepolizumab treatment for hypereosinophilic syndrome
Kuang, F. L., Fay, M. P., Ware, J., Wetzler, L., Holland-Thomas, N., Brown, T., Ortega, H., Steinfeld, J., Khoury, P., & Klion, A. D. (2018) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2018.04.033 · Cited by 94 · see citing works
Eosinophilic granulomatosis with polyangiitis – Advances in pathogenesis, diagnosis, and treatment
Fijołek, J., & Radzikowska, E. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1145257 · Cited by 94 · see citing works
Lung involvement in ANCA-associated vasculitis
Sacoto, G., Boukhlal, S., Specks, U., Flores-Suárez, L. F., & Cornec, D. (2020) · La Presse Médicale · doi:10.1016/j.lpm.2020.104039 · Cited by 91 · see citing works
Anti-IL5 therapy for asthma and beyond
Mukherjee, M., Sehmi, R., & Nair, P. K. (2014) · World Allergy Organization Journal · doi:10.1186/1939-4551-7-32 · Cited by 90 · see citing works
Eosinophils and Disease Pathogenesis
Akuthota, P., & Weller, P. F. (2012) · Seminars in Hematology · doi:10.1053/j.seminhematol.2012.01.005 · Cited by 88 · see citing works
Cottin, V., & Cordier, J.-F. (2012) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2012.08.007 · Cited by 88 · see citing works
Bagnasco, D., Ferrando, M., Varricchi, G., Puggioni, F., Passalacqua, G., & Canonica, G. W. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00135 · Cited by 87 · see citing works
Clinical reviews in allergy and immunology
Leung, D. Y. M., Ledford, D. K., Wechsler, M. E., Fulkerson, P. C., Bochner, B. S., Gauvreau, G. M., Gleich, G. J., Henkel, T., Kolbeck, R., Mathur, S. K., et al. (2012) · Cited by 87 · see citing works
Self-citationPouliquen, I. J., Kornmann, O., Barton, S. V., Price, J. A., & Ortega, H. G. (2015) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cp202446 · Cited by 85 · see citing works
S1-Leitlinie Diagnostik und Therapie der ANCA-assoziierten Vaskulitiden
Schirmer, J. H., Aries, P. M., de Groot, K., Hellmich, B., Holle, J. U., Kneitz, C., Kötter, I., Lamprecht, P., Müller‐Ladner, U., Reinhold‐Keller, E., et al. (2017) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-017-0394-1 · Cited by 82 · see citing works
Chusid, M. J. (2018) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2018.04.031 · Cited by 81 · see citing works
The Immunologic Mechanisms of Eosinophilic Esophagitis
Hill, D. A., & Spergel, J. M. (2016) · Current Allergy and Asthma Reports · doi:10.1007/s11882-015-0592-3 · Cited by 82 · see citing works
Gastrointestinal aspects of vasculitides
Soowamber, M. L., Weizman, A. V., & Pagnoux, C. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.179 · Cited by 77 · see citing works
Treatment of Eosinophilic Granulomatosis with Polyangiitis: A Review
Raffray, L., & Guillevin, L. (2018) · Drugs · doi:10.1007/s40265-018-0920-8 · Cited by 75 · see citing works
Mepolizumab: First Global Approval
Keating, G. M. (2015) · Drugs · doi:10.1007/s40265-015-0513-8 · Cited by 74 · see citing works
Terrier, B., Darbon, R., Durel, C., HACHULLA, E., Karras, A., Maillard, H., Papo, T., Puéchal, X., Pugnet, G., Quéméneur, T., et al. (2020) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-020-01621-3 · Cited by 72 · see citing works
McGeoch, L., Twilt, M., Famorca, L., Bakowsky, V., Barra, L., Benseler, S. M., Cabral, D. A., Carette, S., Cox, G., Dhindsa, N., et al. (2015) · The Journal of Rheumatology · doi:10.3899/jrheum.150376 · Cited by 72 · see citing works
Tailored therapy for severe asthma
Menzella, F., Lusuardi, M., Galeone, C., & Zucchi, L. (2015) · Multidisciplinary Respiratory Medicine · doi:10.1186/2049-6958-10-1 · Cited by 64 · see citing works
Progress in treatment of ANCA-associated vasculitis
Smith, R., Jones, R. B., & Jayne, D. R. W. (2012) · Arthritis Research & Therapy · doi:10.1186/ar3797 · Cited by 63 · see citing works
IL-5 receptor α levels in patients with marked eosinophilia or mastocytosis
Wilson, T. M., Marić, I., Shukla, J., Brown, M. R., Santos, C. S., Šimáková, O., Khoury, P., Fay, M. P., Kozhich, A. T., Kolbeck, R., et al. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.05.032 · Cited by 61 · see citing works
Omalizumab as a Steroid-Sparing Agent in Chronic Eosinophilic Pneumonia
Kaya, H., Gümüş, S., Uçar, E., Aydoğan, M., Muşabak, U., Tozkoparan, E., & Bilgiç, H. (2012) · CHEST Journal · doi:10.1378/chest.11-1881 · Cited by 60 · see citing works
Detoraki, A., Capua, L. D., Varricchi, G., Genovese, A., Marone, G., & Spadaro, G. (2015) · Journal of Asthma · doi:10.3109/02770903.2015.1081700 · Cited by 59 · see citing works
Treatment of ANCA-associated vasculitides (AAV)
Holle, J. U., & Gross, W. L. (2012) · Autoimmunity Reviews · doi:10.1016/j.autrev.2012.08.007 · Cited by 57 · see citing works
Mepolizumab in eosinophilic disorders
Abonia, J. P., & Putnam, P. E. (2011) · Expert Review of Clinical Immunology · doi:10.1586/eci.11.27 · Cited by 56 · see citing works
Bochner, B. S., Book, W., Busse, W. W., Butterfield, J. H., Furuta, G. T., Gleich, G. J., Klion, A. D., Lee, J. J., Leiferman, K. M., Minnicozzi, M., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.07.024 · Cited by 55 · see citing works
Self-citationEleftheriou, D., Gale, H., Pilkington, C., Fenton, M. J., Sebire, N. J., & Brogan, P. A. (2016) · Lara D. Veeken · doi:10.1093/rheumatology/kew029 · Cited by 55 · see citing works
Menzella, F., Lusuardi, M., Galeone, C., Taddei, S., & Zucchi, L. (2015) · Journal of Asthma and Allergy · doi:10.2147/jaa.s40244 · Cited by 54 · see citing works
Biologics for the treatment of autoimmune renal diseases
Holdsworth, S. R., Gan, P., & Kitching, A. R. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.18 · Cited by 53 · see citing works
Novel Targeted Therapies for Eosinophil-Associated Diseases and Allergy
Radonjic‐Hoesli, S., Valent, P., Klion, A. D., Wechsler, M. E., & Simon, H. (2014) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124407 · Cited by 52 · see citing works
Self-citationFaverio, P., Bonaiti, G., Bini, F., Vaghi, A., & Pesci, A. (2018) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s159949 · Cited by 51 · see citing works
Diagnosis and treatment of cutaneous leukocytoclastic vasculitis
Gota, C. E., & Calabrese, L. H. (2013) · International Journal of Clinical Rheumatology · doi:10.2217/ijr.12.79 · Cited by 50 · see citing works
Biologic Agents for the Treatment of Hypereosinophilic Syndromes
Kuang, F. L., & Klion, A. D. (2017) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2017.08.001 · Cited by 50 · see citing works
Vultaggio, A., Nencini, F., Bormioli, S., Vivarelli, E., Dies, L., Rossi, O., Parronchi, P., Maggi, E., & Matucci, A. (2020) · Allergy Asthma and Immunology Research · doi:10.4168/aair.2020.12.5.885 · Cited by 50 · see citing works
Eosinophilia and Kidney Disease: More than Just an Incidental Finding?
Gauckler, P., Shin, J., Mayer, G., & Kronbichler, A. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7120529 · Cited by 45 · see citing works
Berti, A., Boukhlal, S., Groh, M., & Cornec, D. (2019) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2019.1697678 · Cited by 48 · see citing works
Personalized Medicine in Allergy
Ferrando, M., Bagnasco, D., Varricchi, G., Bernardi, S., Bragantini, A., Passalacqua, G., & Canonica, G. W. (2016) · Allergy Asthma and Immunology Research · doi:10.4168/aair.2017.9.1.15 · Cited by 47 · see citing works
Biological therapy for systemic vasculitis: A systematic review
Silva-Fernández, L., Loza, E., Martínez-Taboada, V. M., Blanco, R., Rúa‐Figueroa, Í., Pego‐Reigosa, J. M., & Muñoz‐Fernández, S. (2013) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2013.07.010 · Cited by 46 · see citing works
Anti-interleukin-5 antibody therapy in asthma and allerges
Corren, J. (2011) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0b013e32834c3d30 · Cited by 46 · see citing works
S1-Leitlinie Diagnostik und Therapie der ANCA-assoziierten Vaskulitiden
Schirmer, J. H., & Moosig, F. (2017) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-017-0393-2 · Cited by 46 · see citing works
Updates for the treatment of EGPA
Raffray, L., & Guillevin, L. (2020) · La Presse Médicale · doi:10.1016/j.lpm.2020.104036 · Cited by 40 · see citing works
Real-life evidence of low-dose mepolizumab efficacy in EGPA: a case series
Detoraki, A., Tremante, E., Poto, R., Morelli, E., Quaremba, G., Granata, F., Romano, A., Mormile, I., Rossi, F. W., de Paulis, A., et al. (2021) · Respiratory Research · doi:10.1186/s12931-021-01775-z · Cited by 40 · see citing works
Eosinophils: Offenders or General Bystanders in Allergic Airway Disease and Pulmonary Immunity?
Akuthota, P., Xenakis, J. J., & Weller, P. F. (2011) · Journal of Innate Immunity · doi:10.1159/000323433 · Cited by 38 · see citing works
Thompson, G. E., & Specks, U. (2019) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2019.05.012 · Cited by 38 · see citing works
Anti-IL-5 Pathway Agents in Eosinophilic-Associated Disorders Across the Lifespan
Lombardi, C., Comberiati, P., Ridolo, E., Cottini, M., Yacoub, M., Casagrande, S., Riccò, M., Bottazzoli, M., & Berti, A. (2024) · Drugs · doi:10.1007/s40265-024-02037-0 · Cited by 35 · see citing works
Therapeutic Approaches to Patients With Hypereosinophilic Syndromes
Simon, H., & Klion, A. D. (2012) · Seminars in Hematology · doi:10.1053/j.seminhematol.2012.01.002 · Cited by 35 · see citing works
Hsieh, F. H. (2014) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2014.03.004 · Cited by 34 · see citing works
Insight into IL-5 as a Potential Target for the Treatment of Allergic Diseases
Antosz, K., Batko, J., Błażejewska, M., Gawor, A., Sleziak, J., & Gomułka, K. (2024) · Biomedicines · doi:10.3390/biomedicines12071531 · Cited by 33 · see citing works
Churg-Strauss Syndrome: An Update
Abril, A. (2011) · Current Rheumatology Reports · doi:10.1007/s11926-011-0205-7 · Cited by 33 · see citing works
Terrier, B., Charles, P., Aumaître, O., Bélot, A., Bonnotte, B., Crabol, Y., Durel, C., Ebbo, M., Jourde‐Chiche, N., Lega, J., et al. (2020) · La Presse Médicale · doi:10.1016/j.lpm.2020.104031 · Cited by 33 · see citing works
Control of inflammatory heart disease by CD4+ T cells
Barin, J. G., & Čiháková, D. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12134 · Cited by 33 · see citing works
Na, H. J., Hamilton, R. G., Klion, A. D., & Bochner, B. S. (2012) · Journal of Immunological Methods · doi:10.1016/j.jim.2012.05.017 · Cited by 33 · see citing works
Eosinophilia in Rheumatologic/Vascular Disorders
Tamaki, H., Chatterjee, S., & Langford, C. A. (2015) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2015.05.001 · Cited by 30 · see citing works
Harish, A., & Schwartz, S. A. (2020) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-019-08775-4 · Cited by 30 · see citing works
Current Landscape of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
Lally, L., & Spiera, R. (2014) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2014.09.003 · Cited by 28 · see citing works
Targeting eosinophils: severe asthma and beyond
Caminati, M., Menzella, F., Guidolin, L., & Senna, G. (2019) · Drugs in Context · doi:10.7573/dic.212587 · Cited by 27 · see citing works
Biologics for the Treatment of Allergic Conditions: Eosinophil Disorders
Olivieri, B., Tinazzi, E., Caminati, M., & Lunardi, C. (2020) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2020.07.001 · Cited by 27 · see citing works
Novel Therapies for Eosinophilic Disorders
Bochner, B. S. (2015) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2015.05.007 · Cited by 27 · see citing works
Tsurikisawa, N., Oshikata, C., Watanabe, M., Fukuda, N., Yamaguchi, T., Kiyohara, H., & Kaneko, T. (2021) · International Archives of Allergy and Immunology · doi:10.1159/000514505 · Cited by 26 · see citing works
Pérez, E. R. F., Olson, A. L., & Frankel, S. K. (2011) · Medical Clinics of North America · doi:10.1016/j.mcna.2011.08.006 · Cited by 26 · see citing works
- Authors
- Kim, S., Marigowda, G., Oren, E., Israel, E., & Wechsler, M. E.
- Affiliations
- Boston Children's Hospital (US)
- Brigham and Women's Hospital (US)
- Corresponding author
- Wechsler, Michael E.
- Venue
- Journal of Allergy and Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2010-06
- Volume
- 125
- Issue
- 6
- Pages
- 1336-1343
- ISSN
- 0091-6749 (ISSN-L)
- OpenAlex
- W1972474621
- Cited by
- 280
- References
- 27
- Citations by year
- 2026: 7 · 2025: 7 · 2024: 13 · 2023: 10 · 2022: 9 · 2021: 12 · 2020: 20 · 2019: 20 · 2018: 15 · 2017: 25 · 2016: 25 · 2015: 28 · 2014: 17 · 2013: 18 · 2012: 25
- FWCI
- 16.06
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Allergy and Clinical Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Amgen
- Astellas Pharma US
- GlaxoSmithKline
- Astellas Pharma
- Topics
- Health Sciences › Medicine › Rheumatology › Eosinophilic Disorders and Syndromes
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Vasculitis and related conditions
- Health Sciences › Medicine › Physiology › Asthma and respiratory diseases
- Keywords
- mepolizumab, eosinophilic granulomatosis with polyangiitis, eosinophilic vasculitis, IL-5, anti-IL-5 monoclonal antibody, corticosteroid tapering, steroid-sparing therapy, eosinophilia, disease activity markers, safety and tolerability
- MeSH terms
- Adrenal Cortex Hormones, Adult, Antibodies, Monoclonal, Cell Count, Eosinophils, Female, Humans, Immunotherapy, Male, Middle Aged, Pilot Projects, Sinusitis, Vasculitis, Churg-Strauss Syndrome, Withholding Treatment, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
